
Almirall to focus on respiratory and skin diseases
Catalan Economy
01 Jan 2010
Pharmaceutical group almirall is to focus its r+d investments on new treatments for respiratory diseases such as asthma and chronic obstructive pulmonary disease (copd) and skin problems, particularly psoriasis and skin cancer.
according to almirall's development director pere berga, the company invested nearly eur 100 million in r&d in 2009. the lab also expects to finalize this year clinical trials for eklira, its new drug for copd. in 2009, almirall posted eur 701 million in revenue, with net profit reaching eur 141 million. the group has a team of 550 researchers at its three centers in sant feliu de llobregat, sant just desvern and sant andreu de la barca (barcelona).
source: expansión 25/01/2010
Related News and Success stories.
-
21 Jul 2025
Barcelona's Exponential Day 2025: Vanessa Cann unveils the next AI revolution
-
18 Jul 2025
Catalonia moves up as a Strongly Innovative European Region and leads Spain
-
17 Jul 2025
Grifols invests €160 million in Barcelona and creates 400 jobs with a new plasma fractionation plant
-
16 Jul 2025
Meet the 10 most disruptive companies in Catalonia in 2025